INTERNATIONAL STEM CELL CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0712 USD | +0.14% |
|
-40.67% | +14.84% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
Calendar
2024-05-15
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +14.84% | 570K | |
| -2.11% | 41.35B | |
| +42.15% | 40.38B | |
| +1.46% | 39.05B | |
| -14.19% | 26.67B | |
| +1.98% | 24.07B | |
| -24.65% | 18.36B | |
| -3.88% | 11.68B | |
| +20.74% | 11.6B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- ISCO Stock
- News International Stem Cell Corporation
- Earnings Flash (ISCO) INTERNATIONAL STEM CELL CORPORATION Reports Q4 Loss $-0.11
